114 related articles for article (PubMed ID: 19133206)
1. [Cardiovascular risk of cyclooxygenase selective inhibitors].
Terán-Estrada L; Miranda-Limón JM; Galván-Villegas F
Rev Med Inst Mex Seguro Soc; 2008; 46(3):287-99. PubMed ID: 19133206
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
3. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
4. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
5. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk associated with celecoxib.
Brophy JM
N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
[No Abstract] [Full Text] [Related]
7. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
9. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M; Yin L; Ingelsson E
Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
[TBL] [Abstract][Full Text] [Related]
10. Coxibs: can this class of drugs survive?
Tabrizchi R
Vasc Health Risk Manag; 2005; 1(1):5-8. PubMed ID: 17319092
[No Abstract] [Full Text] [Related]
11. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
12. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
13. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
[No Abstract] [Full Text] [Related]
14. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
15. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Krum H; Liew D; Aw J; Haas S
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
17. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
19. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
20. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
